summarizes the studies with dabigatran or rivaroxaban in APS.
In the literature, about 85 cases of patients with APS who have taken the new oral anticoagulants were found. Most of these papers are case reports or series of cases, besides two retrospective studies and one prospective study. The median follow-up time ranged from 10 to 19 months and the most widely used medication was rivaroxaban. The recurrence ranged from 0 to 17%, including several arterial events, when only studies that reported the number of recurrences in relation to the number of patients at risk who were followed for a period of time were evaluated. The vast majority of patients included in all studies had suffered previous arterial events or multiple recurrences in the presence of vitamin K antagonists, or discontinued the use of the anticoagulant, or, ultimately, were triple-positive for antiphospholipid antibodies. [4] [5] [6] [7] [8] [9] Two prospective randomized studies, one of Italian origin (TRAPS) and another English (RAPS), 3 currently in a follow-up phase of patients with APS, with a group treated with warfarin versus rivaroxaban, were published. These studies will provide the answers to this question.
Currently, based on available studies and also based on experts opinion of on the subject, one should contraindicate the use of these new oral anticoagulants in patients with triple-positivity of antiphospholipid antibodies, in patients with a history of arterial events, and with recurring events. The opinion of experts in this field is that vitamin K antagonists should remain the basis of anticoagulation in patients with APS; direct oral anticoagulants may be considered in the treatment of APS [the first venous event], if there is refractoriness, allergy or a side effect associated with the use of warfarin; on the other hand, these drugs are not suitable in cases of poor adherence or in cases of thrombotic recurrence, notwithstanding therapeutic levels of anticoagulation. 10 
